Iron Uptake and Mucormycosis Pathogenesis
Iron Uptake and Mucormycosis Pathogenesis
批准号:
8889496
负责人:
ASHRAF S. IBRAHIM
金额:
$35.49万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-02-01 至 2016-06-30
关键词:
AcidityAdherenceAdrenal Cortex HormonesAffinityAffinity ChromatographyAgeAngioinvasionAntibodiesAntifungal AgentsAntifungal TherapyBindingBloodBlood VesselsCandida albicansCell CommunicationCell LineCell Membrane ProteinsCell WallCellsChelating AgentsChinese Hamster Ovary CellClinicalCysteineDataDeferoxamineDiabetes MellitusDiabetic KetoacidosisDiseaseEndothelial CellsFutureGenesGlucoseGoalsGrowthHematogenousHematologic NeoplasmsHematopoietic Stem Cell TransplantationHemeImmunocompromised HostImmunotherapeutic agentIn VitroIncidenceInfectionInjuryInvadedIronIron ChelationLifeLigand BindingLigandsMalignant NeoplasmsMediatingMucormycosisMusMycosesNeutropeniaOpen Reading FramesOperative Surgical ProceduresOrgan TransplantationOrganismOryzaOsmolar ConcentrationPathogenesisPatientsPatternPenetrationPhysiologicalPlayPopulationPrevalenceProcessProtein BindingProteinsRNA InterferenceReceptor CellRegulationRelative (related person)ReportingRhizopusRiskRisk FactorsRoleSaccharomyces cerevisiaeSerumSiderophoresTherapeuticUnited StatesVascular Endothelial CellVirulenceZygomycosiscell injurydesignferrioxamine Bfungusglucose-regulated proteinsheme-binding proteinin vivoiron chelation therapyiron metabolismmortalitymouse modelnovelnovel therapeuticsoverexpressionpermeasepreventreceptorreceptor expressionuptake
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Mucormycosis, most commonly caused by Rhizopus oryzae, is a life-threatening infection that occurs in patients immunocompromised by diabetic ketoacidosis (DKA), neutropenia, corticosteroid use, and/or increased serum iron. Because of the rising prevalence of these risk factors, the incidence of mucormycosis has risen. Despite disfiguring surgery and aggressive antifungal therapy, the mortality of mucormycosis remains >40%, and approaches 100% in patients with disseminated disease. Clearly new strategies to prevent and treat mucormycosis are needed. Clinical hallmarks of R. oryzae infection include its remarkable angiotropism and the hypersusceptibility of patients with increased available serum iron to this infection. Patients with elevated levels of available serum iron such as those with DKA or who have received deferoxamine are uniquely susceptible to mucormycosis, but not other fungal infections. Deferoxamine acts as a xeno-siderophore which supplies previously unavailable iron to the fungus. We have shown that iron chelation with chelators that are not utilized by the fungus to obtain iron protects mice from infection with R. oryzae. We also found that the high affinity iron permease (Ftr1p) is critical to the ability of the fungus to obtain iron during infection. Equally important is our recent identification of the iron-regulated GRP78 as a host cell receptor to which R. oryzae binds during the process of invading endothelial cells, a step required for angioinvasion. Finally, we found that anti-Ftr1p or anti-Grp78 antibodies markedly, but not completely, protected DKA mice from infection with R. oryzae. These findings underscore the critical role of iron and invasion of vascular endothelial cells in the organism's virulence strategies. We propose to build on these exciting data to further characterize fungal and host targets that are involved in iron uptake and/or regulated by iron. Our goal is to develop multiple immunotherapeutic strategies that will prove to be synergistic in preventing and/or treating lethal mucormycosis. We will achieve this goal by identifying the fungal ligand involved in mediating binding of R. oryzae to endothelial cell GRP78. We will continue identifying host receptors, other than GRP78, that promote adherence to and/or invasion of and subsequent injury to endothelial cells by R. oryzae. Additionally, we will study the effect of physiological conditions, including iron, on the pattern of GRP78 expression in vivo. Finally, we will identify fungal receptors which act upstream of Ftr1p in mediating iron uptake from the host. Achieving these specific aims will further define the role of iron in the establishment and progression of mucormycosis and define possible novel therapeutic strategies that can be applied concurrently against the disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10338103
-
项目类别:
-
资助金额:$104.73万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens Supplement
-
批准号:10564958
-
项目类别:
-
资助金额:$3.84万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10728900
-
项目类别:
-
资助金额:$8.31万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10535474
-
项目类别:
-
资助金额:$115.18万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens
-
批准号:10084265
-
项目类别:
-
资助金额:$102.25万
-
财政年份:2019
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Humanized monoclonal antibodies to treat mucormycosis
-
批准号:9759762
-
项目类别:
-
资助金额:$29.98万
-
财政年份:2018
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Humanized monoclonal antibodies to treat mucormycosis
-
批准号:10599750
-
项目类别:
-
资助金额:$98.79万
-
财政年份:2018
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections
-
批准号:9089918
-
项目类别:
-
资助金额:$19.71万
-
财政年份:2015
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections
-
批准号:9488843
-
项目类别:
-
资助金额:$45.71万
-
财政年份:2015
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Arf6 Inhibition as Novel Treatment for Multidrug Resistance Gram Negative Infections
-
批准号:9755205
-
项目类别:
-
资助金额:$48.15万
-
财政年份:2015
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
An Ftr1 vaccine to abrogate mucormycosis
-
批准号:8020985
-
项目类别:
-
资助金额:$20.52万
-
财政年份:2010
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
An Ftr1 vaccine to abrogate mucormycosis
-
批准号:7896157
-
项目类别:
-
资助金额:$18.12万
-
财政年份:2010
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS
-
批准号:8174480
-
项目类别:
-
资助金额:$0.41万
-
财政年份:2009
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS
-
批准号:7952233
-
项目类别:
-
资助金额:$0.63万
-
财政年份:2008
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
IRON UPTAKE AND MUCOMYCOSIS PATHOGENESIS
-
批准号:7606192
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2007
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Novel Toxins and Receptors in Mucormycosis Pathogenesis and Treatment
-
批准号:10666383
-
项目类别:
-
资助金额:$55.48万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Novel Antifungal Strategies for Lethal Mucormycosis
-
批准号:7268002
-
项目类别:
-
资助金额:$19.37万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Iron Uptake and Mucormycosis Pathogenesis
-
批准号:8685093
-
项目类别:
-
资助金额:$35.29万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Iron Uptake and Mucormycosis Pathogenesis
-
批准号:7556321
-
项目类别:
-
资助金额:$26.94万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
Iron Uptake and Mucormycosis Pathogenesis
-
批准号:7383193
-
项目类别:
-
资助金额:$26.71万
-
财政年份:2006
-
负责人:ASHRAF S. IBRAHIM
-
依托单位:
海外基金